AntriaBio completes capital raise


Pico cap AntriaBio (ANTB) raises $10M via private placement. The company issued 28,063,323 units comprised of one share of common stock at $0.26 each and one warrant to purchase one share of common at $0.39.

Proceeds to used for general corporate purposes including the development of its lead product, AB101, a once-per-week microsphere insulin formulation.

Comments (1)
  • Healthcare guy
    , contributor
    Comment (1) | Send Message
     
    After MNKD success, this will be a home run. These guys have a once a week formulation of basal insulin, which is ready to go into humans with data in 12 months. No expectation of side effects, since regular insulin is being used. Lantus sells over 5 billion annually in the US alone. Once data is positive, its a billion + dollar valuation.
    3 Apr 2014, 01:25 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs